Iterum Therapeutics plc
ITRM • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Sep 30, 2025
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$1.60M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Healthy liquidity · 1.41Weak profitability
Financial data as of: Sep 30, 2025, 12:00 AM UTCLast earnings update: Nov 14, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.00
Change0.00%
Market Cap$1.60M
52W Range0.03 - 1.42
Beta3.01
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq-11.16
Current Ratio1.41
Quick Ratio1.41
Volume49.30M
Price$0.00
Change0.00%
Market Cap$1.60M
52W Range0.03 - 1.42
Beta3.01
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq-11.16
Current Ratio1.41
Quick Ratio1.41
Volume49.30M
Avg Volume16.33M
EPS Surprise-0.07
Investment DNA
How strong this company looks for long-term investors
38
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
61/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
50/100
Why this score▼
Healthy liquidity · 1.41Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.